These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22113985)

  • 1. Esophageal and gastric cancer incidence and mortality in alendronate users.
    Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
    J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus.
    Schouten LJ; Steevens J; Huysentruyt CJ; Coffeng CE; Keulemans YC; van Leeuwen FE; Driessen AL; van den Brandt PA
    Clin Gastroenterol Hepatol; 2011 Sep; 9(9):754-61. PubMed ID: 21570484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
    Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
    J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication.
    Lassen A; Hallas J; de Muckadell OB
    Gastroenterology; 2005 Oct; 129(4):1179-86. PubMed ID: 16230072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of bisphosphonates and risk of breast cancer.
    Vestergaard P; Fischer L; Mele M; Mosekilde L; Christiansen P
    Calcif Tissue Int; 2011 Apr; 88(4):255-62. PubMed ID: 21253712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
    Vestergaard P
    Calcif Tissue Int; 2012 Jan; 90(1):22-9. PubMed ID: 22120197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure in patients treated with bisphosphonates.
    Grove EL; Abrahamsen B; Vestergaard P
    J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.
    Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF
    Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate.
    Vestergaard P
    Calcif Tissue Int; 2011 Oct; 89(4):265-70. PubMed ID: 21710315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
    Chiang CH; Huang CC; Chan WL; Huang PH; Chen TJ; Chung CM; Lin SJ; Chen JW; Leu HB
    J Bone Miner Res; 2012 Sep; 27(9):1951-8. PubMed ID: 22532232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
    Vestergaard P
    Calcif Tissue Int; 2011 Dec; 89(6):434-41. PubMed ID: 22002678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.
    Lindblad M; Lagergren J; García Rodríguez LA
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):444-50. PubMed ID: 15734971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric and esophagus events before and during treatment of osteoporosis.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 Feb; 86(2):110-5. PubMed ID: 19957165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
    Pazianas M; Abrahamsen B; Eiken PA; Eastell R; Russell RG
    Osteoporos Int; 2012 Nov; 23(11):2693-701. PubMed ID: 22392160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.